Pulmonary delivery of aminoglycoside
First Claim
Patent Images
1. A dispersible powder composition comprising particles comprising an aminoglycoside and a phospholipid for delivery to the lungs by inhalation, wherein the particles have a geometric diameter of less than 5 microns, the composition being effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses, and wherein each respirable unit dose comprises a volume of 0.30 to 0.95 ml.
3 Assignments
0 Petitions
Accused Products
Abstract
A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
465 Citations
33 Claims
- 1. A dispersible powder composition comprising particles comprising an aminoglycoside and a phospholipid for delivery to the lungs by inhalation, wherein the particles have a geometric diameter of less than 5 microns, the composition being effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses, and wherein each respirable unit dose comprises a volume of 0.30 to 0.95 ml.
-
21. A capsule comprising a composition for delivery of aminoglycoside to the lungs by inhalation, the composition including particles comprising phospholipid and aminoglycoside, the aminoglycoside comprising tobramycin, a geometric diameter less than 5 microns, a mass median aerodynamic diameter less than 5 microns, and a bulk density of greater than 0.08 g/cm3, wherein the capsule comprises a volume that is equivalent to, or less than, a capsule volume corresponding to a size #2 capsule, and wherein the capsule contains aminoglycoside or salt thereof, in an amount of 10-60 mg, whereby an effective dose of the aminoglycoside can be administered to the lungs using less than 6 capsules.
-
22. A pulmonary delivery method comprising administering a pharmacologically effective amount of tobramycin to the lungs by providing a composition comprising particles dispersed from less than 6 capsules by an inhalation device, the particles comprising a matrix of phospholipid and;
- tobramycin or a salt thereof, a bulk density of greater than 0.08 g/cm3, and having a pH of 7 or higher, wherein an effective amount of the tobramycin can be administered to the lungs in less than 6 respirable unit doses.
- View Dependent Claims (28, 29)
- 23. A dispersible powder composition comprising particles comprising phospholipid and tobramycin or salt thereof, the particles characterized by a geometric diameter of less than 5 microns, a mass median aerodynamic diameter of less than 5 microns, and a bulk density of between 0.08 g/cm3 and 0.20 g/cm3, wherein the amount of tobramycin or salt thereof in the particles is from about 50% to about 99%, wherein the composition is in the form of a unit dose containing the tobramycin or salt thereof in an amount of 10-60 mg, wherein a therapeutic dose of the tobramycin or salt thereof can be administered to the lungs in less than 6 respirable unit doses, each unit dose comprising a volume of 0.30 mL to 0.95 mL.
Specification